India, Nov. 3 -- BioNTech SE (BNTX), a biotechnology company, on Tuesday announced financial results for the third quarter and nine months ended September 30, 2026.
The company returned to quarterly profitability despite lower revenue, primarily reflecting reduced demand for COVID-19 vaccines. BioNTech also raised the midpoint of its full-year 2026 revenue guidance and reported progress across its oncology pipeline.
BioNTech specializes in developing immunotherapies and vaccines, with a growing focus on oncology. Its research includes mRNA-based cancer immunotherapies, antibody-drug conjugates and combination treatments targeting various cancers.
Q3 Financial Results:
Revenue for the third quarter of 2026 amounted to EUR 1,289.2 million...